Spyre Therapeutics, Inc. (SYRE) Misses Q3 EPS by 54c

Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q3 EPS of ($1.36), $0.54 worse than the analyst estimate of ($0.82).

For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.

You May Also Be Interested In

• Goldman Sachs (GS) Reiterated at Market Perform by Citizens on Constructive Backdrop
• Morgan Stanley (MS) Reiterated at Market Perform by Citizens on Constructive Backdrop
• Eagle Plains and Xcite Define Prospective Geophysical Trends at Don Lake and Smitty Uranium Projects, SK